The clinical–molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
The role of somatostatin and dopamine receptors as molecular targets for the treatment of
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …
Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association …
LV Neto, EO Machado, RM Luque… - The Journal of …, 2009 - academic.oup.com
Context: Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary
adenomas may predict the response to postsurgical therapies. Objectives: Our objectives …
adenomas may predict the response to postsurgical therapies. Objectives: Our objectives …
Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies
R Srirajaskanthan, J Watkins, L Marelli, K Khan… - …, 2009 - karger.com
Introduction: Somatostatin and dopamine receptors are both G-protein-coupled receptors.
Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well …
Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well …
Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience
E Macchia, M Gasperi, M Lombardi, L Morselli… - Journal of …, 2009 - Springer
Background and aim: The management of pituitary adenomas secreting TSH has evolved
considerably over the last decades. We report the clinical features, management, and …
considerably over the last decades. We report the clinical features, management, and …
[PDF][PDF] The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
C Verslype, S Carton, I Borbath, T Delaunoit… - Acta gastro-enterologica …, 2009 - ageb.be
Somatostatin analogs (SSAs) have an important role in the management of patients with
neuroendocrine tumours of the gastro intestinal tract and pancreas (GEP NETs). These …
neuroendocrine tumours of the gastro intestinal tract and pancreas (GEP NETs). These …
Lanreotide Autogel® in the Treatment of Acromegaly
F Roelfsema, NR Biermasz… - Clinical Medicine …, 2009 - journals.sagepub.com
Background In acromegaly expert surgery is curative in only about 60% of patients.
Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its …
Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its …
[PDF][PDF] New molecular strategies for prevention of fibroproliferative vascular disease: An experimental approach to restenosis
NM Tigerstedt - 2009 - helda.helsinki.fi
Atherosclerosis and vasculoproliferative disorders are major health concerns, causing
excess humane suffering, having great economical consequences, and contributing to over …
excess humane suffering, having great economical consequences, and contributing to over …
[PDF][PDF] Leonardo Vieira Neto, Evelyn de O. Machado, Raul M. Luque, Giselle F. Taboada, Jorge B. Marcondes, Leila MC Chimelli, Leonardo Pereira Quintella, Paulo …
Objectives: Our objectives were to assess and compare the mRNA levels of DR1-5 and
somatostatin receptors 1–5 in normal pituitaries (NPs), nonfunctioning pituitary adenomas …
somatostatin receptors 1–5 in normal pituitaries (NPs), nonfunctioning pituitary adenomas …
Diego Ferone, Federico Gatto, Marica Arvigo, Eugenia Resmini, Mara Boschetti
C Teti, D Esposito, F Minuto - Journal of Molecular …, 2009 - jme.bioscientifica.com
The role of somatostatin and dopamine receptors as molecular targets for the treatment of
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …
patients with pituitary adenomas is well established. Indeed, dopamine and somatostatin …